• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Sponsored Post
    • Make a Contribution
    • Technology Job Posting
  • Technology Events 2022-2023
  • Technology Domains
  • Technology Markets
  • Venture Capital
  • Contact
    • About

Illumina Announces a New Genotyping Array and Scientific Contribution to Three Genome Centers to Support the All of Us Research Program

December 7, 2018 By Technologies.org Leave a Comment

Illumina, Inc. (NASDAQ: ILMN) today announced the launch of its new high-density genotyping array, the Infinium™ Global Diversity Array. This new array was developed for and inspired by the All of Us Research Program. The All of Us Research Program is a historic effort to gather data from one million or more people living in the United States, to accelerate human disease research and improve health. The All of Us Research Program is one of the country’s most ambitious biomedical research efforts ever undertaken. It aims to build a nationwide community of at least one million participants from all walks of life, including groups that have been historically underrepresented in research.

In September, the All of Us Research Program awarded funds totaling $28.6 million to three genome centers around the country. These centers will generate genomic data from biosamples contributed by the program’s participants. Ultimately, this information will become a critical component in the program’s precision medicine research platform, a national resource to support studies on a variety of important health questions. The All of Us Research Program is funded and led by the National Institutes of Health (NIH), part of the U.S. Department of Health and Human Services.

Recognizing the significant impact that this project will have on the future of healthcare, Illumina is making a scientific contribution to the program by providing the new Infinium™ Global Diversity Array to process up to 1 million samples to the three genome centers, at no charge. The new array will be a high-density chip that has been designed to enable achievement of the primary genotyping-based goals of the project. Those goals are unparalleled coverage of a highly diverse cohort and the ability to return results to participants such as those indicated by the ACMG-59 Gene List and key pharmacogenomic variants. Some of these genes are associated with potentially life-threatening health conditions, ranging from familial hypercholesterolemia, to breast and ovarian cancer. The array will become commercially available for others to use in mid-2019.

“A core value of the All of Us Research Program is to reflect the rich diversity of the United States. Including people who have been underrepresented in biomedical research will help researchers understand existing health disparities and ensure that everyone can benefit from future breakthroughs,” commented Eric Dishman.

In addition to the new genotyping array, the awarded genome centers will employ Illumina’s NovaSeq 6000 Sequencing Platform to conduct the whole genome sequencing for the All of Us Research Program.

“This contribution to the selected All of Us Genome Centers will allow the program to accelerate the unprecedented effort to complete genotyping and sequencing for all 1 million or more people who participate in the program,” said NIH Director Francis S. Collins, M.D., Ph.D.

“We are privileged to make this scientific contribution to the All of Us Research Program Genome Centers,” shared Francis deSouza, President and Chief Executive Officer of Illumina. “This landmark initiative will build awareness of the unprecedented benefits that DNA sequencing can have on improving the human condition. It is an innovative program that will contribute to driving down the cost of sequencing, while further unlocking the power of the human genome.”

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Related

Filed Under: Tech

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Research

CybersecurityMarket.com (Cybersecurity Market): Advanced hackers succeeded in breaking in to Apple’s most guarded fortress
GenZnomads.com: Gen Z Nomads Want to Work from Home
MetaversePolling.com (Metaverse Polling): What Do Consumers Think of the Metaverse?
Qutrit.app: Qutrits are at the cutting edge of quantum computing
CryptoExchange.Tokyo: Japan’s $1 trillion market for cryptocurrency trading
MoscowRules.com (Moscow Rules): A Perfect Title for Publication Covering Russian Affairs
Decoy Networks: “decoys become your only way of hiding”

Market Analysis

Luxury-Home Sales Sink 18%, the Biggest Decline Since the Start of the Pandemic
The U.S. Army’s Long-Range Hypersonic Weapon (LRHW)
E-commerce pure play doesn’t require the heavy outsourcing
Global Wealth Grew by Double Digits to $530 Trillion in 2021, Despite Continued Crises
Event Calendar
Market Size Matters
Critical Mineral Shortages Could Disrupt Global Supply Chains

Tech Events

Fira de Barcelona celebrates the extension of MWC Barcelona until 2030
Jamstack Conf 2022, November 7-8 2022, San Francisco and online
Photonics Industry Summit, September 21, 2022, Washington, DC

Secondary Sidebar

Venture Capital

Strapi Secures $31 Million in Series B Funding to Further Develop Open Source Headless Content Management System and Deliver Cloud Platform
0x Labs Raises $70M Led By Greylock, to Continue Expanding Web3’s Core Exchange Infrastructure
Razorpay has raised $375M at a valuation of $7.5B
With $25 Million In Funding, Atomic Launches an Investing API For Fintechs and Banks
Canditech raises $9 million seed round from Insight Partners and StageOne Ventures to create a world without resumes
Clix, Multi-Platform Streamer, Raises $10 Million Series A Funding
Taptap Send raises $65M to build cross-border remittances
Domains for Startups
Number of UK unicorns worth more than $1bn grew to 116 in 2021
Storyblok Raises $47M Series B Led by Mubadala Capital and HV Capital to Make Headless Content Management the New Standard

Footer

Recent Posts

  • Oracle Becomes First Hyperscaler to Open a Cloud Region in Mexico
  • Ceres and Shell announce electrolyser agreement for green hydrogen
  • Datadog Launches Audit Trail to Help Businesses Achieve Their Compliance and Governance Objectives
  • Samsung Unveils ISOCELL Image Sensor with Industry’s Smallest 0.56μm Pixel
  • Box Launches Technology Collaboration with FUJIFILM Business Innovation
  • VivaTech, Europe’s number one startup and tech event, makes its big comeback with more than 91,000 participants in Paris
  • Cloudflare Expands Its Zero Trust Platform to Become the Only Cloud-Native Provider with Network Scale
  • New Zealand’s leading port, Ports of Auckland, welcome the world’s first full sized, electric tugboat
  • Energy Dome Successfully Launches First CO2 Battery Long-Duration Energy Storage Plant in the World
  • Resilience Announces $625 Million Series D Financing to Expand Network, Bring Innovative Technologies to Biomanufacturing

Media Partners

  • VPNW
  • S3H
  • OPINT
  • Press Media Release
  • OSINT
  • Digital Market
  • Briefly

Media Partners

  • Technology Conferences
  • Event Sharing Network
  • Defense Conferences
  • Cybersecurity Events
  • Event Calendar
  • Calendarial
  • Opinion
  • Venture Capital

Copyright © 2015 Technologies.org

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT